- Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024
- Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024
- Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154
- Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity
- Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis
- Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154
- Lipocine Announces Financial Results for the Full Year Ended December 31, 2023
- Lipocine to Present at 36th Annual Roth Conference
More ▼
Key statistics
On Thursday, Lipocine Inc (LPCN:NAQ) closed at 6.54, -8.53% below its 52-week high of 7.15, set on Apr 11, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.60 |
---|---|
High | 6.60 |
Low | 6.35 |
Bid | 6.46 |
Offer | 6.55 |
Previous close | 6.54 |
Average volume | 30.68k |
---|---|
Shares outstanding | 5.35m |
Free float | 5.19m |
P/E (TTM) | -- |
Market cap | 34.98m USD |
EPS (TTM) | -1.71 USD |
Data delayed at least 15 minutes, as of May 23 2024 20:59 BST.
More ▼